Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
JAK Inhibitor
The First People's Hospital of Lianyungang
Dermatomyositis, Adult Type
1 trial -
KANG FU PEN
The First People's Hospital of Lianyungang
Cervical Cancer
1 trial -
Keverprazan
The First People's Hospital of Lianyungang
H. Pylori Infection
1 trial -
Lecanemab 10 mg/kg
The First People's Hospital of Lianyungang
Alzheimer s Disease
1 trial -
Levocarnitine Injection
The First People's Hospital of Lianyungang
Renal Dialysis
1 trial -
Levothyroxine
The First People's Hospital of Lianyungang
Heart Failure
1 trial -
Live Combined Bifidobacterium and Lactobacillus
The First People's Hospital of Lianyungang
Functional Constipation
1 trial -
Longidaza
The First People's Hospital of Lianyungang
Bacterial Vaginosis
1 trial -
Low dose Oliceridine
The First People's Hospital of Lianyungang
Oliceridine
1 trial -
Maggot debridement therapy
The First People's Hospital of Lianyungang
Diabetic Foot Ulcers
1 trial -
Mesalazine
The First People's Hospital of Lianyungang
Ulcerative Colitis, Unspecified
1 trial -
Methimazole
The First People's Hospital of Lianyungang
Graves Disease
1 trial -
Minocycline
The First People's Hospital of Lianyungang
Ischemic Stroke, Acute
2 trials -
Montelukast
The First People's Hospital of Lianyungang
Sinusitis
1 trial -
Nerve block with liposomal bupivacaine and intravenous analgesia
The First People's Hospital of Lianyungang
Liposomal Bupivacaine
1 trial -
Nifedipine GITS
The First People's Hospital of Lianyungang
Hypertension
1 trial -
Nocardia rubra Cell Wall Skeleton
The First People's Hospital of Lianyungang
Diabetic Foot Ulcer
1 trial -
Optimal hypoglycemic treatment
The First People's Hospital of Lianyungang
Type2 Diabetes
1 trial -
Ornithine aspartate granule
The First People's Hospital of Lianyungang
Non-alcoholic Fatty Liver Disease
1 trial -
PCIA group
The First People's Hospital of Lianyungang
Postoperative Pain
1 trial -
PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
PEG-somatropin
The First People's Hospital of Lianyungang
Growth Hormone Deficiency
1 trial -
Parecoxib
The First People's Hospital of Lianyungang
Postoperative Pain Management, Pain Threshold, Shoulder Pain, Laparoscopies
1 trial -
Parecoxib
The First People's Hospital of Lianyungang
Emergence Delirium
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources